Alar Pharmaceuticals Inc. (TPEX:6785)
Taiwan · Delayed Price · Currency is TWD 97.80
-1.30 (-1.31%)
Jul 30, 2026, 9:34 AM CST
Alar Pharmaceuticals Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,620 | 20,307 | 9,452 | 11,942 | 6,555 | 2,608 | |
Market Cap Growth | -33.71% | 114.84% | -20.85% | 82.17% | 151.37% | -6.63% |
Enterprise Value | 4,319 | 17,972 | 7,028 | 11,326 | 6,046 | 2,053 |
Last Close Price | 99.10 | 304.00 | 141.26 | 208.00 | 114.18 | 45.42 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 520.21 | 31.21 | - | - |
Forward PE | - | 223.48 | 246.09 | - | - | - |
PS Ratio | 2204.42 | 7376.39 | 1624.93 | 25.45 | 8193.75 | - |
PB Ratio | 2.80 | 8.45 | 3.79 | 13.31 | 12.74 | 4.88 |
P/TBV Ratio | 2.80 | 8.45 | 3.79 | 13.31 | 12.74 | 4.88 |
P/FCF Ratio | - | - | - | 30.06 | - | - |
P/OCF Ratio | - | - | - | 29.59 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | - | 6528.21 | 1208.22 | 24.14 | 7557.22 | - |
EV/EBITDA Ratio | - | - | - | 29.22 | - | - |
EV/EBIT Ratio | - | - | - | 29.38 | - | - |
EV/FCF Ratio | - | - | - | 28.51 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0 | 0.00 | 0.01 | 0.00 |
Debt / EBITDA Ratio | - | - | - | 0.00 | - | - |
Debt / FCF Ratio | - | - | - | 0.00 | - | - |
Net Debt / Equity Ratio | -0.97 | -0.95 | -0.97 | -1.00 | -0.94 | -0.97 |
Net Debt / EBITDA Ratio | 12.35 | 13.87 | 37.14 | -2.31 | 10.95 | 5.71 |
Net Debt / FCF Ratio | 14.74 | 13.19 | 22.62 | -2.25 | 14.19 | 7.97 |
Asset Turnover | 0.00 | 0.00 | 0.00 | 0.63 | 0.00 | - |
Quick Ratio | 24.61 | 30.84 | 44.14 | 11.98 | 90.70 | 116.51 |
Current Ratio | 25.01 | 31.59 | 44.33 | 12.08 | 92.66 | 118.67 |
Return on Equity (ROE) | -4.64% | -3.26% | 1.07% | 54.21% | -3.79% | -11.34% |
Return on Assets (ROA) | -4.69% | -4.16% | -2.41% | 32.22% | -5.47% | -10.20% |
Return on Invested Capital (ROIC) | -212.65% | -195.31% | -104.19% | 2250.88% | -197.02% | -336.68% |
Return on Capital Employed (ROCE) | -7.90% | -7.00% | -2.70% | 42.90% | -9.00% | -17.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.70% | -0.39% | 0.19% | 3.20% | -0.30% | -2.46% |
FCF Yield | -2.36% | -0.86% | -1.14% | 3.33% | -0.52% | -2.49% |
Dividend Yield | 0.09% | 0.03% | 0.18% | 0.72% | - | - |
Payout Ratio | - | - | 551.46% | - | - | - |
Buyback Yield / Dilution | 0.02% | -0.87% | -16.08% | -0.09% | - | -14.21% |
Total Shareholder Return | 0.11% | -0.84% | -15.90% | 0.63% | - | -14.21% |